← All drugs
Drug · FAERS side-effect profile with label screen

Oxycodone and Acetaminophen side effects: what 12,035 FDA adverse event reports show

Oxycodone Hydrochloride And Acetaminophen · 1,195 reaction terms · 392,242 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Not stated in label

Label matched

Oxycodone (Oxycodone Hydrochloride)

closest FDA label found for this product string; brand list suppressed because the label is a related product, not an exact match

Who reports

12,035 reports · 70% serious · 1,613 with death outcome · 63% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Oxycodone hydrochloride (HCl) tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, misuse, overdo.

FDA label, Indications and Usage

What it is

Oxycodone HCl tablets, USP contains oxycodone, an opioid agonist.

FDA label, Description section

Boxed warning

SERIOUS AND LIFE-THREATENING RISKS FROM USE OF OXYCODONE HCl Addiction, Abuse, and Misuse Because the use of oxycodone HCl exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which c.

FDA label
How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Labeled — boxed warning 1Labeled adverse reaction 2Labeled (related wording) 4Reporting / coding artifact 3Lab value / disease marker 5Not in label — unassessed 25
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,155 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Grip strength101165.4
127.4–214.7ROR 165.6 · calibrated p 4e-9 ✓
91.3 EB05 77.3 · IC025 +5.7
3/3 methods agree
Not in label — unassessedserious n=38 · ♀ 100% (drug 63%) · 100% clinicianno trial arm names this drug
Dependence18,814109.5
107.7–111.3ROR 135.2 · calibrated p 1e-8 ✓
72.3 EB05 71.4 · IC025 +6.1
3/3 methods agree
Labeled adverse reaction
exact term
serious PRR 7.5 · ♀ 39% (drug 63%) · 100% consumerno trial arm names this drug
Swollen joint count5155.7
40.9–75.8ROR 55.7 · calibrated p 1e-5 ✓
43.5 EB05 34.4 · IC025 +4.5
3/3 methods agree
Not in label — unassessedserious n=29 · ♀ 100% (drug 63%) · 100% clinicianno trial arm names this drug
Drug withdrawal syndrome neonatal2,91951.7
49.6–53.8ROR 53.2 · calibrated p 9e-6 ✓
41.6 EB05 40.4 · IC025 +5.3
3/3 methods agree
Labeled adverse reaction
exact term
serious PRR 35.5 · ♀ 43% (drug 63%) · 100% consumerno trial arm names this drug
Vision abnormal neonatal7545.8
35.7–58.8ROR 45.9 · calibrated p 3e-5 ✓
37.5 EB05 30.9 · IC025 +4.5
3/3 methods agree
Not in label — unassessedserious n=71 · 100% consumerno trial arm names this drug
Learning disorder39541.1
36.9–45.8ROR 41.3 · calibrated p 4e-5 ✓
34.5 EB05 31.7 · IC025 +4.9
3/3 methods agree
Not in label — unassessed–no trial arm names this drug
Opisthotonus12740.1
33.2–48.5ROR 40.1 · calibrated p 6e-5 ✓
33.7 EB05 29.0 · IC025 +4.6
3/3 methods agree
Not in label — unassessed–no trial arm names this drug
Poor feeding infant14834.2
28.7–40.7ROR 34.3 · calibrated p 1e-4 ✓
29.4 EB05 25.7 · IC025 +4.5
3/3 methods agree
Not in label — unassessed–no trial arm names this drug
Lupus vulgaris15932.8
27.8–38.8ROR 32.9 · calibrated p 2e-4 ✓
28.4 EB05 24.9 · IC025 +4.5
3/3 methods agree
Not in label — unassessedserious n=100 · ♀ 100% (drug 63%) · 100% clinicianno trial arm names this drug
Speech disorder developmental38232.5
29.2–36.2ROR 32.6 · calibrated p 2e-4 ✓
28.2 EB05 25.9 · IC025 +4.6
3/3 methods agree
Not in label — unassessed–no trial arm names this drug
Deep vein thrombosis postoperative25031.1
27.2–35.5ROR 31.2 · calibrated p 2e-4 ✓
27.1 EB05 24.4 · IC025 +4.5
3/3 methods agree
Not in label — unassessedserious n=184 · ♀ 100% (drug 63%) · 96% clinicianno trial arm names this drug
Drug diversion65327.4
25.2–29.7ROR 27.6 · calibrated p 4e-4 ✓
24.3 EB05 22.8 · IC025 +4.5
3/3 methods agree
Reporting / coding artifactserious n=20 · 75% consumerno trial arm names this drug
X-ray abnormal18925.2
21.7–29.3ROR 25.2 · calibrated p 7e-4 ✓
22.5 EB05 20.0 · IC025 +4.2
3/3 methods agree
Lab value / disease markerserious n=130 · ♀ 100% (drug 63%) · 95% clinicianno trial arm names this drug
Ill-defined disorder6,42825.2
24.5–25.8ROR 26.8 · calibrated p 5e-4 ✓
22.6 EB05 22.1 · IC025 +4.5
3/3 methods agree
Not in label — unassessedage-adj. PRR 26.3 · serious PRR 22.2 · ♀ 86% (drug 63%)no trial arm names this drug
Adjustment disorder with depressed mood20323.8
20.6–27.5ROR 23.9 · calibrated p 9e-4 ✓
21.4 EB05 19.1 · IC025 +4.1
3/3 methods agree
Not in label — unassessedserious n=145 · ♀ 100% (drug 63%) · 96% clinicianno trial arm names this drug
Developmental delay90023.3
21.8–25.0ROR 23.6 · calibrated p 9e-4 ✓
21.1 EB05 20.0 · IC025 +4.3
3/3 methods agree
Not in label — unassessedserious PRR 55.3 · ♀ 42% (drug 63%) · 100% consumerno trial arm names this drug
Polysubstance abuse6021.8
16.7–28.5ROR 21.8 · calibrated p 0.002 ✓
19.8 EB05 15.9 · IC025 +3.7
3/3 methods agree
Reporting / coding artifact–no trial arm names this drug
Anti-cyclic citrullinated peptide antibody6221.8
16.8–28.3ROR 21.8 · calibrated p 0.002 ✓
19.7 EB05 15.9 · IC025 +3.7
3/3 methods agree
Lab value / disease markerserious n=49 · ♀ 100% (drug 63%) · 100% clinicianno trial arm names this drug
C-reactive protein8120.8
16.6–26.2ROR 20.8 · calibrated p 0.002 ✓
19.0 EB05 15.7 · IC025 +3.7
3/3 methods agree
Lab value / disease markerserious n=63 · ♀ 100% (drug 63%) · 95% clinicianno trial arm names this drug
Porphyria acute12320.8
17.3–25.0ROR 20.8 · calibrated p 0.002 ✓
19.0 EB05 16.3 · IC025 +3.8
3/3 methods agree
Not in label — unassessedserious n=77 · ♀ 100% (drug 63%) · 92% clinicianno trial arm names this drug
Dislocation of vertebra19820.8
18.0–24.0ROR 20.8 · calibrated p 0.002 ✓
19.0 EB05 16.8 · IC025 +3.9
3/3 methods agree
Not in label — unassessedserious n=137 · ♀ 100% (drug 63%) · 94% clinicianno trial arm names this drug
Duodenal ulcer perforation64720.6
19.0–22.3ROR 20.7 · calibrated p 0.002 ✓
18.8 EB05 17.6 · IC025 +4.1
3/3 methods agree
Not in label — unassessedserious PRR 105.0 · ♀ 100% (drug 63%) · 93% clinicianno trial arm names this drug
Anti-cyclic citrullinated peptide antibody positive61520.1
18.5–21.9ROR 20.3 · calibrated p 0.002 ✓
18.5 EB05 17.3 · IC025 +4.1
3/3 methods agree
Lab value / disease markerserious PRR 104.5 · ♀ 100% (drug 63%) · 93% clinicianno trial arm names this drug
Facet joint syndrome27220.1
17.7–22.7ROR 20.1 · calibrated p 0.002 ✓
18.4 EB05 16.6 · IC025 +4.0
3/3 methods agree
Not in label — unassessedserious n=162 · ♀ 100% (drug 63%) · 93% clinicianno trial arm names this drug
Learning disability44118.9
17.2–20.9ROR 19.0 · calibrated p 0.003 ✓
17.4 EB05 16.1 · IC025 +3.9
3/3 methods agree
Not in label — unassessedserious n=339 · ♀ 40% (drug 63%) · 100% consumerno trial arm names this drug
Swollen joint count increased25218.7
16.4–21.3ROR 18.7 · calibrated p 0.003 ✓
17.2 EB05 15.5 · IC025 +3.9
3/3 methods agree
Lab value / disease markerserious n=200 · ♀ 100% (drug 63%) · 96% clinicianno trial arm names this drug
Retinitis13318.4
15.4–22.0ROR 18.4 · calibrated p 0.003 ✓
17.0 EB05 14.7 · IC025 +3.7
3/3 methods agree
Not in label — unassessedserious n=76 · ♀ 100% (drug 63%) · 100% clinicianno trial arm names this drug
Folliculitis77317.2
16.0–18.5ROR 17.3 · calibrated p 0.004 ✓
16.0 EB05 15.0 · IC025 +3.9
3/3 methods agree
Not in label — unassessedserious PRR 103.4 · ♀ 100% (drug 63%) · 93% clinicianno trial arm names this drug
Attention deficit hyperactivity disorder29216.1
–ROR 16.1 · –
–Not in label — unassessedserious n=7no trial arm names this drug
Withdrawal syndrome2,89315.6
15.1–16.2ROR 16.1 · calibrated p 0.005 ✓
14.6 EB05 14.2 · IC025 +3.8
3/3 methods agree
Labeled — boxed warning
exact term
age-adj. PRR 3.7 · serious PRR 8.4 · 87% consumerno trial arm names this drug
Overdose14,26115.0
14.7–15.2ROR 17.4 · calibrated p 0.004 ✓
14.0 EB05 13.9 · IC025 +3.8
3/3 methods agree
Reporting / coding artifactage-adj. PRR 2.9 · serious PRR 3.1no trial arm names this drug
Rheumatic fever28614.9
13.2–16.8ROR 14.9 · calibrated p 0.007 ✓
13.9 EB05 12.6 · IC025 +3.6
3/3 methods agree
Not in label — unassessedserious n=217 · ♀ 100% (drug 63%) · 94% clinicianno trial arm names this drug
Helicobacter infection66614.9
13.7–16.1ROR 15.0 · calibrated p 0.007 ✓
13.9 EB05 13.1 · IC025 +3.7
3/3 methods agree
Not in label — unassessedserious PRR 82.1 · ♀ 100% (drug 63%) · 94% clinicianno trial arm names this drug
Toxicity to various agents9,58012.9
12.6–13.1ROR 14.2 · calibrated p 0.009 ✓
12.2 EB05 12.0 · IC025 +3.6
3/3 methods agree
Not in label — unassessedage-adj. PRR 1.8 · serious PRR 1.5no trial arm names this drug
Primary sequestrum4912.0
9.0–16.0ROR 12.0 · calibrated p 0.019 ✓
11.1 EB05 8.6 · IC025 +2.9
3/3 methods agree
Not in label — unassessed–no trial arm names this drug
Hand deformity68611.8
10.9–12.7ROR 11.8 · calibrated p 0.018 ✓
11.2 EB05 10.5 · IC025 +3.3
3/3 methods agree
Not in label — unassessedserious PRR 66.8 · ♀ 99% (drug 63%) · 93% clinicianno trial arm names this drug

Clinical concept groups

MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.

ConceptReportsPRR 95% CIReading
Dependence / withdrawal1,1176.66.2–7.0signal
Liver injury7404.34.0–4.6signal
Depression6153.83.5–4.1signal
Serious infection1,4453.33.1–3.4signal
Interstitial lung disease1592.92.5–3.4signal
Pancreatitis1292.82.3–3.3signal
Suicidality3642.62.3–2.9signal
Fall / fracture4862.22.0–2.4signal
Hyperglycaemia / diabetes4202.11.9–2.3raised
Kidney injury5051.91.8–2.1raised
Gi bleeding2021.91.7–2.2raised
Rhabdomyolysis / myopathy831.81.4–2.2raised
Thrombocytopenia2061.61.4–1.9raised
Anaemia2371.41.2–1.6raised
Opportunistic infection1061.41.1–1.6raised
Venous thromboembolism1681.41.2–1.6raised

Trial evidence (ClinicalTrials.gov)

ClinicalTrials.gov returned results-bearing trials mentioning Oxycodone and Acetaminophen only as a background or rescue medication (NCT02625181, NCT04296396); no trial listing it as the tested intervention was cached, so no trial cross-check is shown.

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Dependence18,814109.5
107.7–111.3ROR 135.2 · calibrated p 1e-8 ✓
72.3 EB05 71.4 · IC025 +6.1
3/3 methods agree
Labeled adverse reaction
exact term
serious PRR 7.5 · ♀ 39% (drug 63%) · 100% consumerno trial arm names this drug
Death16,2884.1
4.0–4.2ROR 4.7 · calibrated p 0.268
4.0 EB05 4.0 · IC025 +2.0
3/3 methods agree
Outcome field, not a reaction
boxed warning mentions mortality
age-adj. PRR 1.4 · serious PRR 0.9no trial arm names this drug
Overdose14,26115.0
14.7–15.2ROR 17.4 · calibrated p 0.004 ✓
14.0 EB05 13.9 · IC025 +3.8
3/3 methods agree
Reporting / coding artifactage-adj. PRR 2.9 · serious PRR 3.1no trial arm names this drug
Toxicity to various agents9,58012.9
12.6–13.1ROR 14.2 · calibrated p 0.009 ✓
12.2 EB05 12.0 · IC025 +3.6
3/3 methods agree
Not in label — unassessedage-adj. PRR 1.8 · serious PRR 1.5no trial arm names this drug
Ill-defined disorder6,42825.2
24.5–25.8ROR 26.8 · calibrated p 5e-4 ✓
22.6 EB05 22.1 · IC025 +4.5
3/3 methods agree
Not in label — unassessedage-adj. PRR 26.3 · serious PRR 22.2 · ♀ 86% (drug 63%)no trial arm names this drug
Pain5,9952.1
2.0–2.1ROR 2.2 · calibrated p 0.971
2.1 EB05 2.0 · IC025 +1.0
3/3 methods agree
Likely indication confounding
term in indications; also in warnings
age-adj. PRR 4.6 · serious PRR 4.7no trial arm names this drug
Nausea4,7021.3
1.2–1.3ROR 1.3 · calibrated p 0.499
1.3 EB05 1.2 · IC025 +0.3Labeled adverse reaction
exact term
age-adj. PRR 2.1 · serious PRR 2.2no trial arm names this drug
Drug dependence4,5896.2
6.0–6.3ROR 6.4 · calibrated p 0.125
6.0 EB05 5.9 · IC025 +2.5
3/3 methods agree
Reporting / coding artifactage-adj. PRR 5.7 · serious PRR 6.3 · ♀ 39% (drug 63%) · 96% consumerno trial arm names this drug
Fatigue (tiredness)4,5721.3
1.2–1.3ROR 1.3 · calibrated p 0.488
1.3 EB05 1.2 · IC025 +0.3Labeled adverse reaction
exact term
age-adj. PRR 3.1 · serious PRR 4.0no trial arm names this drug
Drug ineffective (drug did not work)4,5000.7
0.7–0.7ROR 0.7 · calibrated p 0.138
0.7 EB05 0.7 · IC025 -0.5
PRR-only: not supported by EBGM or IC
Reporting / coding artifactage-adj. PRR 2.3 · serious PRR 2.6no trial arm names this drug
Dyspnoea (shortness of breath)3,3291.3
1.2–1.3ROR 1.3 · calibrated p 0.485
1.3 EB05 1.2 · IC025 +0.3Labeled adverse reaction
exact term
age-adj. PRR 3.1 · serious PRR 3.3 · ♀ 83% (drug 63%)no trial arm names this drug
Diarrhoea (diarrhea)3,3181.1
1.1–1.1ROR 1.1 · calibrated p 0.376
1.1 EB05 1.1 · IC025 +0.1Labeled adverse reaction
exact term
age-adj. PRR 2.2 · serious PRR 2.4no trial arm names this drug
Headache3,2731.1
1.1–1.2ROR 1.1 · calibrated p 0.386
1.1 EB05 1.1 · IC025 +0.1Labeled adverse reaction
exact term
age-adj. PRR 2.4 · serious PRR 3.1 · ♀ 85% (drug 63%)no trial arm names this drug
Vomiting3,0511.4
1.3–1.4ROR 1.4 · calibrated p 0.578
1.4 EB05 1.3 · IC025 +0.4Labeled adverse reaction
exact term
age-adj. PRR 2.6 · serious PRR 2.5no trial arm names this drug
Anxiety3,0182.3
2.2–2.4ROR 2.3 · calibrated p 0.897
2.3 EB05 2.2 · IC025 +1.1
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 3.8 · serious PRR 4.7no trial arm names this drug

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

✓ A hand-written Bradford Hill causality assessment exists for this drug: Oxycodone ↔ Drug dependence / withdrawal syndrome.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Oxycodone and Acetaminophen?

In FDA FAERS, the most frequently co-reported reaction terms for Oxycodone and Acetaminophen are dependence, toxicity to various agents, ill-defined disorder, pain, nausea, fatigue. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Oxycodone and Acetaminophen have an FDA boxed warning?

Yes. The current FDA label carries a boxed warning: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF OXYCODONE HCl Addiction, Abuse, and Misuse Because the use of oxycodone HCl exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which c.

Do FAERS signals prove that Oxycodone and Acetaminophen causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.